Company Profile

Acer Therapeutics Inc. is a pharmaceutical company, which is focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs. The Companyâ€™s product pipeline includes OLPRUVA (sodium phenylbutyrate), ACER-801 (osanetant) and EDSIVO (celiprolol). OLPRUVA (sodium phenylbutyrate) for oral suspension is a formulation of sodium phenylbutyrate powder, for the treatment of various inborn errors of metabolism, including urea cycle disorders (UCDs) and Maple Syrup Urine Disease (MSUD). Its ACER-801 (osanetant) is an investigational non-hormonal, neurokinin 3 receptor (NK3R) antagonist for the treatment of asomotor symptoms (VMS), post-traumatic stress disorder (PTSD), and prostate cancer. Its EDSIVO (celiprolol) is a selective adrenergic modulator for the treatment of vascular Ehlers-Danlos syndrome (vEDS) in patients with a confirmed type III collagen (COL3A1) mutation.

Employees

Sector

Biotechnology & Medical Research

More about the company

23-11-20	Acer Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI
23-11-20	Chris Schelling Ceases to Be Chief Executive Officer of Acer Therapeutics Inc	CI
23-11-20	Harry S. Palmin Ceases to Be Chief Financial Officer of Acer Therapeutics Inc	CI
23-11-20	Acer Therapeutics Inc. Announces Executive Changes	CI
23-11-20	Zevra Therapeutics Completes Acer Acquisition	MT
23-11-16	Zevra Therapeutics, Inc. completed the acquisition of Acer Therapeutics Inc. from funds affiliated with TVM Capital Life Science and others.	CI
23-11-16	Zevra Therapeutics, Inc. completed the acquisition of Acer Therapeutics Inc. from funds affiliated with TVM Capital Life Science and others.	CI
23-11-13	Acer Therapeutics Inc.(OTCPK:ACER) dropped from S&P TMI Index	CI
23-11-08	Acer Therapeutics Inc. - Shareholder/Analyst Call
23-11-08	Acer Therapeutics Inc.(OTCPK:ACER) dropped from NASDAQ Composite Index	CI
23-09-05	HC Wainwright Downgrades Acer Therapeutics to Neutral From Buy	MT
23-09-01	Top Midday Decliners	MT
23-09-01	Roth MKM Downgrades Acer Therapeutics to Neutral From Buy, Price Target is $1.50	MT

23-09-05	HC Wainwright Downgrades Acer Therapeutics to Neutral From Buy	MT
23-09-01	Roth MKM Downgrades Acer Therapeutics to Neutral From Buy, Price Target is $1.50	MT

23-11-02	Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Acer Therapeutics Shareholders Vote "FOR" the Proposed Merger and Related Proposals	AQ
23-10-10	ACER THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Acer Therapeutics Inc. - ACER	BU
23-09-05	ACER THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Acer Therapeutics Inc. - ACER	BU
23-08-31	Zevra Therapeutics to Acquire Acer Therapeutics, Expanding its Rare Disease Portfolio and Adding Commercial Product	AQ
23-08-30	Acer Therapeutics Reacquires Worldwide Development, Commercialization and Economic Rights to OLPRUVA™ from Relief Therapeutics, Excluding the Geographical Europe	AQ

23-08-30	Relief Therapeutics conclut un accord de licence avec Acer pour Olpruva
23-08-30	Relief Therapeutics schliesst Lizenz-Abkommen mit Acer für Olpruva
23-05-01	Relief-Partner Acer mit Fortschritten bei Vermarktung von Olpruva
23-04-14	Relief Therapeutics rutscht 2022 tiefer in Verlustzone
23-03-15	Relief-Partner Acer forciert Vermarktung von Olpruva

Date	Insider	Type	Main position	Quantity	% Market Cap.
23-11-16	Jefferson Davis	Issuer sale	CHIEF BUSINESS OFFICER	71,645	0.2929%
23-11-16	John Dunn	Issuer sale	Director	27,380	0.1119%
23-11-16	Stephen Aselage	Issuer sale	Chairman	483,741	1.9774%

Acer Therapeutics Inc. Stock

Stocks

ACER

US00444P1084

Biotechnology & Medical Research

Latest news : Acer Therapeutics Inc.

Analysts' recommendations: Acer Therapeutics Inc.

Press Releases: Acer Therapeutics Inc.

News in other languages: Acer Therapeutics Inc.

Quotes and Performance

Latest insider transactions

Bio Therapeutic Drugs

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ACER THERAPEUTICS INC.	-17.95%	-19.50%	-	-	16.15M
ARGENX SE	+4.43%	+2.49%	+61.83%	+115.25%	52.88B
WUXI APPTEC CO., LTD.	+1.58%	+14.12%	+72.87%	+85.18%	50.98B
BIONTECH SE	-0.23%	-0.98%	-14.12%	-16.00%	22.81B
INSMED INCORPORATED	+0.98%	+9.05%	-0.36%	+423.40%	22.43B
WUXI BIOLOGICS (CAYMAN) INC.	-1.27%	+6.18%	+30.56%	-15.11%	17.01B
GENMAB A/S	+0.88%	+5.78%	+30.82%	-34.26%	15.91B
PHARMAESSENTIA CORPORATION	+3.02%	+12.74%	+143.33%	+308.04%	13.58B
EXELIXIS, INC.	+0.68%	+2.54%	+22.28%	+168.03%	13.29B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+0.48%	+5.71%	+27.63%	-	12.56B
Average	-0.75%	+6.25%	+41.65%	+129.32%	24.61B
Weighted average by Cap.	+1.71%	+6.70%	+46.30%	+120.54%